What is the optimal management for preventing saphenous vein graft diseases?: early results of intravascular angioscopic assessment

Circ J. 2007 Feb;71(2):286-7. doi: 10.1253/circj.71.286.

Abstract

Background: The predominant mechanism of early failure of saphenous vein grafts (SVG) after coronary bypass remains unclear, so angioscopy was used to identify the morphological changes.

Methods and results: Of the 31 SVGs assessed 15 had both yellow plaque and thrombi, whereas in the remaining 16 SVGs the intima was clear white. The serum low-density lipoprotein cholesterol level was significantly higher in the diseased SVG group. Eight patients of the normal SVG group were prescribed ticlopidine, compared with only 1 from the diseased SVG group (p=0.015).

Conclusions: This is the first direct demonstration of yellow plaque and/or thrombosis in SVGs by intravascular angioscopy. In addition to the importance of prescribing statins, it might be vital to also add ticlopidine to aspirin therapy.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angioscopy / methods*
  • Anticoagulants / therapeutic use*
  • Aspirin / therapeutic use
  • Coronary Artery Bypass / methods
  • Graft Occlusion, Vascular / prevention & control*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Middle Aged
  • Platelet Aggregation Inhibitors / therapeutic use
  • Saphenous Vein / pathology*
  • Saphenous Vein / transplantation*
  • Ticlopidine / therapeutic use

Substances

  • Anticoagulants
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Platelet Aggregation Inhibitors
  • Ticlopidine
  • Aspirin